Clovis CEO Sees Rosy Future With Rubraca

 
• By Kevin Grogan

Success in the ARIEL3 trial for its ovarian cancer agent and a collaboration with Bristol-Myers Squibb has put Clovis in a healthy position, CEO Patrick Mahaffy tells Scrip.

Agreement
Clovis CEO Mahaffy: We have never put up 'for sale' sign and never will • Source: Shutterstock

More from Anticancer

More from Therapy Areas